Loading market data...
Thursday, August 20, 2026
Back to HomeKorea StockPremiumAll Kolon Industries coverage

Kolon Industries (120110.KS) Q1 2026: Operating Profit Surges 130% as Chemical Materials Hit 12.8% Margin

Share
Kolon Industries (120110.KS) Q1 2026: Operating Profit Surges 130% as Chemical Materials Hit 12.8% Margin

Kolon Industries (120110.KS) Q1 2026: Operating Profit Surges 130% as Chemical Materials Hit 12.8% Margin

With flat top-line growth masking a decisive structural shift, Kolon Industries' Chemical Materials division generated 71% of consolidated operating profit from just 27.8% of revenue — a profitability asymmetry that redefines where the company's value now lives.

Source: Quarterly Report (Q1 2026, 17th Fiscal Year) — Filed April 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions

Unlimited U.S.-market analysis, $9.99/month

Kolon Industries (120110.KS) Q1 2026: Operating Profit Surges 130% as Chemical Materials Hit 12.8% Margin

This article became available on July 9, 2026. Subscribe to read in full, or wait until October 7, 2026 when it becomes free.

Cancel anytime. Full refund within 7 days.

Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.

NewsFinanceMarkets

Go deeper than the headline

You just read what happened. Here's how to read what it means.

Free daily briefing

The U.S. market, every morning — free

LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.

Get LineVest Daily — free →
This company

Full report on Kolon Industries

We read Kolon Industries's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.

$12 · one-time

Get the Kolon Industries report
Every name you watch

Follow the whole market

Reading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.

$9.99 · monthly

Subscribe

Independent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.